Multi-center Clinical Observation of Reyanning Mixture in Treatment of COVID-19

Ming-bo YANG; Shuang-suo DANG; Sheng HUANG; Yuan-jun LI; Ya-ling GUO

doi:10.13422/j.cnki.syfjx.20201321

您当前的位置：

首页 >

文章列表页 >

Multi-center Clinical Observation of Reyanning Mixture in Treatment of COVID-19

Topic on Epidemic Resistance (Ⅳ) | 更新时间：2020-09-09

- Multi-center Clinical Observation of Reyanning Mixture in Treatment of COVID-19
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 14, Pages: 7-12(2020)
- 作者机构：
  
  1. 西安市第八医院，西安 710061
  2. 西安交通大学第二附属医院，西安 710004
  3. 松滋市人民医院，湖北松滋 434200
  4. 延安市第二人民医院，陕西延安 716000
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201321
  CLC： R22;R242;R2-031;R287
- Published Online：18 March 2020，
  
  Published：20 July 2020
- 稿件说明：
移动端阅览
杨明博,党双锁,黄胜等.热炎宁合剂治疗新型冠状病毒肺炎的多中心临床观察[J].中国实验方剂学杂志,2020,26(14):7-12.

YANG Ming-bo,DANG Shuang-suo,HUANG Sheng,et al.Multi-center Clinical Observation of Reyanning Mixture in Treatment of COVID-19[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(14):7-12.
杨明博,党双锁,黄胜等.热炎宁合剂治疗新型冠状病毒肺炎的多中心临床观察[J].中国实验方剂学杂志,2020,26(14):7-12. DOI： 10.13422/j.cnki.syfjx.20201321.

YANG Ming-bo,DANG Shuang-suo,HUANG Sheng,et al.Multi-center Clinical Observation of Reyanning Mixture in Treatment of COVID-19[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(14):7-12. DOI： 10.13422/j.cnki.syfjx.20201321.

摘要

目的

前期通过冠状病毒疫毒袭肺证病证结合小鼠模型体内实验验证，热炎宁合剂对人新型冠状病毒肺炎（COVID-19）有显著的治疗作用，本次研究进一步评价热炎宁合剂治疗COVID-19的临床疗效，为临床用药提供依据。

方法

选取2020年1月21日至2020年3月2日在西安市第八医院、西安交通大学第二附属医院、湖北省松滋市人民医院、延安市第二人民医院就诊，符合新型冠状病毒肺炎诊断标准普通型患者54例，其中5例不符合方案规定，未予分析，治疗组26例，在化学药物治疗基础上给予热炎宁合剂，对照组23例，给予化学药物治疗，比较两组患者中医证候（咽干咽痛、咳嗽、发热、乏力、胸闷、流涕、鼻塞、头痛）评分，完全退热时间（d），新型冠状病毒核酸检测转阴率及胸部CT缓解率。

结果

与对照组治疗后比较，治疗组除咳嗽、乏力外，其余症状均消失，咽干咽痛、咳嗽、乏力、胸闷、头痛等症状评分，差异有统计学意义（

0.05）；治疗组中位完全退热时间为3 d，较对照组缩短2 d；胸部CT缓解率，治疗组为88.46%（23/26），高于对照组的73.91%（17/23），两组比较差异无统计学意义；病毒核酸检测转阴率，治疗组为96.15%（25/26），对照组为60.87%（14/23），治疗组高于对照组（

0.01）。

结论

热炎宁合剂能改善新型冠状病毒肺炎患者临床症状，促进胸部CT好转，缩短患者发热时间，提高核酸转阴率，为临床治疗提供依据。

Abstract

Objective

In the early stage

in vivo

experiments of coronavirus infection and pulmonary syndrome syndrome combined with mouse model verified that Reyanning mixture has a significant therapeutic effect on human coronavirus disease-2019 (COVID-19). This study further evaluated the clinical efficacy of Reyanning mixture in the treatment of COVID-19

providing a basis for clinical medication.

Method

Patients were collected from January 21

2020 to February 24

2020 in Xi'an No. 8 Hospital

Second Affiliated Hospital of Xi'an Jiaotong University

Yan'an Second People's Hospital and Songzi People's Hospital. 54 common-type patients who met the diagnostic criteria of COVID-19 were enrolled in this study

5 patients of them were not included in the statistical analysis because they did not meet the requirements

including 26 cases in the treatment group using Reyanning mixture on the basis of chemical drug treatment

and 23 cases in the control group receiving chemical drug treatment only. The symptom disappearance rates (throat dryness

throat pain

cough

fever

fatigue

chest tightness

runny nose

nasal congestion

headache)

time to complete fever clearance (d)

the nucleic acid conversion rate and time to recovery on chest CT were compared between two groups.

Result

After treatment

except cough and fatigue

other symptoms disappeared in the treatment group

and the disappearance rate of symptoms such as dry throat

cough

fatigue

chest tightness and headache was statistically significant compared with the control group (

0.05). The median time to complete fever clearance in the treatment group was 3 days

which was 2 days shorter than that in control group. The remission rate of chest CT was 88.46% (23/26) in the treatment group

which was higher than 73.91% (17/23) in control group. The negative conversion rate of viral nucleic acid detection was 96.15% (25/26) in treatment group

higher than 60.87% (14/23) in control group (

0.01).

Conclusion

Reyanning mixture can improve the clinical symptoms of COVID-19 patients

promote the improvement of chest CT. Can shorten the duration of fever.Can improve the novel coronavirus nucleic acid conversion rate

providing a basis for clinical treatment.

关键词

Keywords

references

国家卫生与健康委员会 . 截至 3 月 12 日 24 时新型冠状病毒肺炎疫情最新情况 [EB/OL]. http://www.nhc.gov.cn/xcs/yqtb/202003/816e6f71236b4dca 96378df5f6f4ae53.shtml http://www.nhc.gov.cn/xcs/yqtb/202003/816e6f71236b4dca 96378df5f6f4ae53.shtml , 2020-3-12 / 2020-3-13 .

人民日报 . 最新！中国以外 53124 例，意大利伊朗均过万 [EB/OL]. https://mp.weixin.qq.com/s/ePn0UJZ8ogltNb3JkHQ_kQ.html https://mp.weixin.qq.com/s/ePn0UJZ8ogltNb3JkHQ_kQ.html , 2020-3-13 / 2020-3-13 .

孙中吉，李玉明，吉金利，等 . 26例SARS患者的中西医结合治疗效果观察 [J]. 中国中西医结合急救杂志， 2003 ， 10 ( 4 )： 217 - 219 .

中华人民共和国国家卫生与健康委员会 . 新型冠状病毒肺炎诊疗方案(试行第七版) [EB/OL]. http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294 a7dfe4cef80dc7f5912eb1989.shtml http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294 a7dfe4cef80dc7f5912eb1989.shtml , 2020-03-04 / 2020-03-13 .

黄小波，李宗信，李斌，等 . 中西医结合治疗SARS的临床疗效观察 [J]. 中国中医药信息杂志， 2004 ， 11 ( 2 )： 144 - 145 .

王海，褚亚军，刘英副，等 . 热炎宁合剂治疗小儿急性上呼吸道感染多中心临床研究 [J]. 天津中医药， 2019 ， 36 ( 2 )： 141 - 144 .

袁杰，胡以信，卢玉蓉 . 热炎宁合剂治疗小儿上呼吸道感染180例临床研究 [J]. 四川医学， 2014 ， 35 ( 2 )： 219 - 221 .

杜宝静，陈素萍，王志东 . 开喉剑喷雾剂(儿童型)联合热炎宁合剂治疗普通型手足口病的疗效观察 [J]. 中国当代医药， 2013 ， 20 ( 13 )： 120 - 121 .

傅恩清，刘伟，孙瑞琳，等 . 热炎宁合剂治疗感冒临床观察 [J]. 中国中医急症， 2010 ， 19 ( 4 )： 572 - 573 .

陕西省卫生健康委员会 . 陕西省新型冠状病毒感染的肺炎中医药治疗方案（试行第二版） [EB/OL]. http://guide.medlive.cn/guideline/201532020.2.1 html http://guide.medlive.cn/guideline/201532020.2.1 html , 2020-02-01 / 2020-03-13 .

包蕾，时宇静，耿子涵，等 . 热炎宁合剂在评价人冠状病毒肺炎疫毒袭肺证中的应用 [J]. 中国中药杂志， 2020 ， doi： 10.19540/j.cnki.cjcmm.20200303.401 http://dx.doi.org/10.19540/j.cnki.cjcmm.20200303.401 .

国家卫生健康委员会 . 新型冠状病毒感染的肺炎诊疗方案(试行第三版) [EB/OL]. http://www.nhc.gov.cn/xcs/zhengcwj/202001/470b128 513fe46f086d 79667db9f76a5.shtml http://www.nhc.gov.cn/xcs/zhengcwj/202001/470b128 513fe46f086d 79667db9f76a5.shtml , 2020 - 01 - 22 / 2020-03-13 .

国家卫生健康委员会 . 新型冠状病毒感染的肺炎诊疗方案(试行第四版) [EB/OL]. http://www.nhc.gov.cn/xcs/zhengcwj/202002/573340613ab243b3a7f6 1df260551dd4.shtml http://www.nhc.gov.cn/xcs/zhengcwj/202002/573340613ab243b3a7f6 1df260551dd4.shtml , 2020-01-27 / 2020-03-13 .

国家卫生健康委办公厅，国家中医药管理局办公室 . 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第五版)的通知 [EB/OL]. http://www. Nhc. Gov.cn/xcs/zhengcwj/202002 /d4b895337e19445f8d728fc af1e3e13a. shtml http://www. Nhc. Gov.cn/xcs/zhengcwj/202002 /d4b895337e19445f8d728fc af1e3e13a. shtml , 2020-02-05 / 2020-03-13 .

中华人民共和国卫生部 . 中药新药临床研究指导原则 [M]. 北京：中国医药科技出版社， 2002 ： 168 - 189 .

林琳，唐光华，欧爱华，等 . 103例SARS住院患者中医证候规律探讨 [J] 中医杂志， 2004 ， 45 ( 1 )： 51 - 52 .

管汉雄，熊颖，申楠茜，等 . 武汉2019新型冠状病毒(2019-nCoV)肺炎的临床影像学特征初探 [J]. 放射学实践 , 2020 , doi: 10.13609/j.cnki.1000-0313.2020.02.001 http://dx.doi.org/10.13609/j.cnki.1000-0313.2020.02.001 .

XU X ， CHEN P ， WANG J ， et al . Evolution of the novel corona virus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission [J]. Sci China Life Sci , 2020 , doi: 10.1007 /s11427-020-1637-5 http://dx.doi.org/10.1007 /s11427-020-1637-5 .

WANG M ， CAO R ， ZHANG L ， et al . Remdesivir andchloroquine effectively inhibit the recently emerged novelcoronavirus (2019-nCoV) in vitro [J]. Cell Res ， 2020 , doi： 10.1038/s41422-020-0282-0 http://dx.doi.org/10.1038/s41422-020-0282-0 .

中国新闻网 . 多种“特效药”均在临床试验科学不能急 [EB/OL]. http://www.chinanews.com/sh/2020/02-08 /9083261.shtml http://www.chinanews.com/sh/2020/02-08 /9083261.shtml , 2020-02-08 / 2020-03-12 .

蒋华良，饶子和 . 这些老药和中药或对新型肺炎有治疗作用 [EB/OL]. 经济日报-中国经济网 , http://www.ce.cn/xwzx/gnsz/gdxw/202001/25/t20200125_34187294.shtml http://www.ce.cn/xwzx/gnsz/gdxw/202001/25/t20200125_34187294.shtml , 2020 - 01 - 25 / 2020-03-13 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of Inhibitory Mechanism of Reyanning Mixture Combined with Linezolid Against MRSA and Its Biofilm Based on Metabonomics

Treatment of Myocardial Injury from Coronavirus Disease-2019 by Chinese Medicine

Investigation of Research Strategy of Chinese Medicine Nasal Preparations for Treating Coronavirus Disease-2019 Based on Theory of Lung Opening at Nose ——Taking Qingkailing Preparation as an Example

Exploration of Prevention and Treatment of COVID-19 by Regulating Mucosal Immune System with Traditional Chinese Medicine

Analysis of Key Varieties and Rational Allocation of Traditional Chinese Medicine Resources Under COVID-19 Epidemic Situation

Related Author

Yong TAN

Cheng-qiang DU

Li LI

Jian-feng YI

Mei BAO

Ya-jun CHU

Wei-feng YANG

Cheng LYU

Related Institution

Tsinghua Deren Xi'an Happiness Pharmaceutical Co. Ltd.

Experimental Research Center，China Academy of Chinese Medical Sciences

School of Chemical and Biological Engineering，Yichun University

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

China Association of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰